Pharmaceutical

Novelion Therapeutics (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced that a U.S. District Court judge has sentenced Novelion subsidiary Aegerion Pharmaceuticals. As quoted in the press release: Aegerion’s global settlement consists of a series of agreements, including the criminal plea agreement, which, if all of the …

Novelion Therapeutics (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced that a U.S. District Court judge has sentenced Novelion subsidiary Aegerion Pharmaceuticals.
As quoted in the press release:

Aegerion’s global settlement consists of a series of agreements, including the criminal plea agreement, which, if all of the agreements are finally approved, would result in an approximately $40.1 million aggregate penalty to be paid over three years. This includes the restitution fund described above as well as a civil penalty of $4.1 million to be paid to the SEC pursuant to an SEC Judgment, and $28.8 million, including $2.7 million designated for certain states, to be paid pursuant to the DOJ Civil Settlement Agreement, which is subject to final approval by a U.S. District Court Judge.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20748.58+216.40
TSXV724.19+9.53
DOW33212.96+575.77
S&P 5004158.24+100.40
NASD12131.13+390.48
ASX7105.90-49.30

COMMODITIES

Commodities
Gold1853.77+0.71
Silver22.10+0.07
Copper4.32+0.07
Palladium2072.50+64.50
Platinum957.00+8.00
Oil115.10+1.01
Heating Oil3.91+0.06
Natural Gas8.73-0.17

DOWNLOAD FREE REPORTS

×